GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. Includes a PDE3/4 inhibitor for COPD plus programs in oncology, respiratory, ...

Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. AML patients showed early signs of benefit, but safety concerns led to an ...

Progression-free survival and overall survival were significantly greater in the combination therapy group compared to ...

Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.

Medical cannabis has a high discontinuation rate among patients with chronic musculoskeletal pain, particularly in the first ...

First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data ...